Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Dose Escalation, Safety and Tolerability Study of NX-2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies

NCT04830137 is registered in ClinicalTrials.gov with Nurix Therapeutics, Inc. as lead sponsor.

NCT NCT04830137
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04830137 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Dose Escalation, Safety and Tolerability Study of NX-2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies
Lead sponsor
Nurix Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
May 5, 2021
Completion date
May 31, 2027
Enrollment
248 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia (cll), diffuse large b-cell lymphoma (dlbcl), follicular lymphoma (fl), mantle cell lymphoma (mcl), marginal zone lymphoma (mzl), primary central nervous system lymphoma (pcnsl), small lymphocytic lymphoma (sll), waldenstrom macroglobulinemia (wm)